Key facts
- It has raised $1.6M; the latest was Early Stage VC in Aug 2025.
- Notable investors include CITIC Capital, Qingdao Fund of Venture Capital Funds Management Center, Next Capital (China), Yan Zhao, Zhuopu Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Zeno Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Zeno Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zeno Biotechnology
Developer of synthetic biology and fermentation engineering products. The company mainly uses new generation gene editing technology such as CRISPR-Cas9 to genetically target E. coli, Saccharomyces cerevisiae and other chassis microorganisms, as well as industrialising the products of these strains through fermentation and isolation processes.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2020
- Website
- zenobiotech.cn/
- Ownership
- Privately Held (backing)
Zeno Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zeno Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zeno Biotechnology in its N-PORT filings yet. We sweep new filings monthly.